Navigation Links
Children's National researcher receives ACCP Distinguished Investigator Award
Date:9/8/2008

The American College of Clinical Pharmacology (ACCP) has awarded John van den Anker, MD, PhD, director of Pediatric Clinical Pharmacology at Children's National Medical Center, its annual Distinguished Investigator Award.

Dr. van den Anker, a neonatologist by training, receives this award for "his sustained and prolific contributions to pediatric clinical pharmacology," according to the ACCP.

The Distinguished Investigator Award is given yearly and recognizes superior scientific expertise and accomplishments by a senior investigator, usually involving a distinct area of research in basic or clinical pharmacology for which the individual is internationally known.

Dr. van den Anker is the director of Pediatric Clinical Pharmacology at Children's National Medical Center, and also serves as associate director of Children's Research Institute's Center for Clinical and Community Research. He is professor of Pediatrics, Pharmacology, and Physiology at the George Washington University School of Medicine and Health Sciences, and holds the Evan and Cindy Jones Chair in Pediatric Clinical Pharmacology at Children's National. He has received several major awards from the National Institutes of Health and has published more than 150 peer reviewed papers in the field of neonatal and pediatric clinical pharmacology. He also served as the president of the European Society of Developmental, Perinatal, and Pediatric Pharmacology from 2006-2008.


'/>"/>

Contact: Jennifer Leischer
jleische@cnmc.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Page: 1

Related biology news :

1. Corporate Safe Specialists Launches International Sales Efforts
2. New chemical radar among national security innovations in ACS podcast
3. International team reveals first prognosticator of survival in aggressive cancer
4. White House announces 2007 National Medal of Science laureates
5. National security remedies among topics at surveillance confab
6. Duke Medicine physician-scientist receives National Medal of Science
7. National Research Council report on security at federally managed dams
8. Food, health get top billing at national chemistry meeting
9. Childrens national co-leads nationwide study of landmark sickle cell treatment
10. Story tips from the US Department of Energys Oak Ridge National Laboratory, August 2008
11. [video] Michael DePasquale, CEO of BIO-key International, Inc., Discusses Q2 2008 Revenue Growth on WallSt.nets 3-Minute Press Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2016)... TORONTO , 19 de diciembre de 2016 /PRNewswire/ ... que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado que ... de tumor en 2017, con múltiples sitios previstos a lo largo ... ... en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica que ...
(Date:12/15/2016)... 15, 2016   WaferGen Bio-systems, Inc. (NASDAQ: ... company, announced today that on December 13, 2016, it ... The Nasdaq Stock Market LLC which acknowledged that, as ... WaferGen,s common stock had been at $1.00 or greater ... compliance with Listing Rule 5550(a)(2) of the Nasdaq Stock ...
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017 AquaBounty Technologies, ... on enhancing productivity in aquaculture and a majority-owned subsidiary ... that it has completed the listing of its common ... equity subscription from Intrexon. "AquaBounty,s listing on ... will broaden our exposure to the U.S. markets as ...
(Date:1/19/2017)... Yorba Linda, Ca (PRWEB) , ... January 18, ... ... interactive virtual events for tech innovators, engineers, and scientists from around the world, ... Corporate American News. The awards program is based entirely on merit and decided ...
(Date:1/19/2017)... ... 19, 2017 , ... DaVita Clinical Research (DCR), ... and device development, and Prism Clinical Research , a leader in providing ... Verified Clinical Trials (VCT) has been selected by both companies as an ...
(Date:1/19/2017)... Md. , Jan. 18, 2017  Northwest Biotherapeutics, ... developing DCVax® personalized immune therapies for operable and inoperable ... Bosch , Chief Technical Officer of NW Bio, will ... January 19, 2017, at the Hyatt Regency Hotel in ... Bosch will chair the session entitled "New Therapeutic Approaches ...
Breaking Biology Technology: